Fibrosis Pulmonar Idiopática

The n e w e ng l a n d j o u r na l of m e dic i n e
Review Article
Dan L. Longo, M.D., Editor
Idiopathic Pulmonary Fibrosis

David J. Lederer, M.D., and Fernando J. Martinez, M.D.
T
he family of interstitial lung diseases is characterized by From the Departments of Medicine and
cellular proliferation, interstitial inflammation, fibrosis, or a combination Epidemiology, Columbia University Irving
Medical Center (D.J.L.), and the Depart-
of such findings within the alveolar wall that is not due to infection or ment of Medicine, Weill Cornell Medical
cancer.1 Interstitial fibrosis is the predominant phenotype in most cases. The major- Center (F.J.M.) — both in New York. Ad-
ity of patients with interstitial fibrosis ultimately receive a diagnosis of chronic dress reprint requests to Dr. Martinez at
the Division of Pulmonary and Critical
hypersensitivity pneumonitis (due to mold or bird exposure), pulmonary sarcoidosis, Care Medicine, Joan and Sanford I. Weill
an underlying autoimmune disease, or if no cause is identified, an idiopathic inter- Department of Medicine, Weill Cornell
stitial pneumonia (see Glossary) (Fig. 1). The most common idiopathic interstitial Medical College, New York–Presbyterian
Hospital/Weill Cornell Medical Center,
pneumonia is idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fibrotic New York, NY 10021, or at fjm2003@
interstitial lung disease of unknown cause, often with characteristic imaging and med.cornell.edu.
histologic appearances (described below), that occurs primarily in older adults.2 N Engl J Med 2018;378:1811-23.
IPF is of particular clinical interest because it is often misdiagnosed and managed DOI: 10.1056/NEJMra1705751
inappropriately with immunosuppressive therapy, it is associated with a high mor- Copyright © 2018 Massachusetts Medical Society.
tality rate, and therapies that slow disease progression are now available.
Epidemiol o gy
IPF occurs worldwide. The prevalence of the disease appears to be increasing, al-
though it is unclear whether this reflects increased recognition or a true increase
in incidence. The incidence of IPF appears to be higher in North America and
Europe (3 to 9 cases per 100,000 person-years) than in South America and East
Asia (fewer than 4 cases per 100,000 person-years).3 In the United States, the
prevalence of IPF has been reported to range from 10 to 60 cases per 100,000,
although in one study, the prevalence was 494 cases per 100,000 in 2011 among
adults over the age of 65 years, which was twice as high as the prevalence re-
corded 10 years earlier.4-6 Increasing rates of hospital admissions and deaths due
to IPF also suggest an increasing burden of disease.3,7,8
Cl inic a l Pr e sen tat ion

Clinicians should consider interstitial lung disease in the differential diagnosis for
adults presenting with unexplained exertional dyspnea, chronic dry cough, or Velcro-
like crackles on examination (Table 1). Exertional dyspnea typically progresses
over a period of months to years. In practice, patients with interstitial lung disease
often initially receive a diagnosis of heart failure or chronic obstructive pulmonary
disease,9 suggesting that clinicians frequently fail to consider interstitial lung dis-
ease in patients with dyspnea. In some cases, patients have presented with dyspnea
and dry cough up to 5 years before interstitial lung disease was diagnosed.9 Early
recognition and accurate diagnosis are likely to improve outcomes through avoid-
ance of potentially harmful therapies (e.g., glucocorticoids for IPF)10 and prompt
initiation of therapies that are effective even in the early stages of disease.11,12
Spirometry should be performed and lung volumes and the diffusing capacity
n engl j med 378;19 nejm.org May 10, 2018 1811

The New England Journal of Medicine
Downloaded from nejm.org at UNIVERSIDAD PONTIFICIA BOLIVARIANA on February 18, 2020. For personal use only. No other uses without permission.
Copyright © 2018 Massachusetts Medical Society. All rights reserved.
Glossary
Chronic hypersensitivity pneumonitis: An interstitial lung disease characterized by peribronchiolar and interstitial chronic
inflammatory infiltrates and interstitial fibrosis with or without poorly formed granulomas.
Ground-glass opacities: Hazy areas of increased lung attenuation on CT imaging.
Honeycombing: Thick-walled, linear clusters of cysts on CT, which are often subpleural. Honeycombing represents lung
fibrosis.
Idiopathic interstitial pneumonia: Any one of nine interstitial lung diseases of unknown cause.
Mosaic attenuation: Ground-glass opacities alternating with lucent (or hyperlucent) lung on CT. Mosaic attenuation is
suggestive of small-airway involvement (e.g., hypersensitivity pneumonitis).
Proteostatic dysregulation: Abnormalities in the synthesis, trafficking, folding, or turnover of intracellular proteins.
Reconstruction kernel: The algorithm used to generate CT images. Higher (sharper) kernels provide better spatial resolu-
tion and are preferred for high-resolution CT imaging.
Reticulation: Short, irregular, linear opacities on CT. Reticulation typically represents fibrosis.
Traction bronchiectasis: Dilated bronchi on CT due to peripheral retraction resulting from lung fibrosis.
of the lung for carbon monoxide (DLco) should more established disease, bilateral reticular infil-
be measured in patients with suspected intersti- trates, hazy opacities, and reduced inspiratory lung
tial lung disease. These studies typically identify volumes on chest radiographs should prompt
a reduced forced vital capacity (FVC), a reduced consideration of interstitial lung disease. In IPF,
total lung capacity, and a reduction in DLco.2 bilateral reticulation is often predominant in the
However, spirometric results and lung volumes lower lung zones.
can be normal during the early stages of inter-
stitial lung disease or when emphysema is also Pathobiol o gic Fe at ur e s
present.13 Chest radiographs may be normal or a nd R isk Fac t or s
show nonspecific findings in early disease. In
A favored conceptual model of the pathogenesis
of IPF posits that recurrent, subclinical epithelial
injury superimposed on accelerated epithelial ag-
Other ILDs, Idiopathic ing leads to aberrant repair of the injured alveo-
Pneumo-
10% pulmonary lus and deposition of interstitial fibrosis by
fibrosis,
conioses, 20%
myofibroblasts (Fig. 2). Senescence of alveolar
10% epithelial cells and fibroblasts appears to be a
central phenotype that promotes lung fibrosis.14
Chronic
hypersensitivity
Shortened telomeres, oxidative injury, proteostatic
Sarcoidosis,
20% pneumonitis, dysregulation and endoplasmic reticulum stress,
20%
and mitochondrial dysfunction lead to decreased
CTD-ILD, alveolar epithelial-cell proliferation and secretion
20% of profibrotic mediators.14,15 Mutations in TERT,
TERC, PARN, and RTEL1 — genes involved in the
maintenance of telomere length — are associ-
ated with an increased risk of IPF.16,17 Variations
Figure 1. Estimated Relative Distribution of Specific
Interstitial Lung Diseases (ILDs) in the United States. in genes (DSP, AKAP13, CTNNA, and DPP9) that
These estimates are based on our experience and are are responsible for cell adhesion, integrity, and
likely to be heavily influenced by regional variation in mechanotransduction (the generation of electri-
referral patterns and the true underlying prevalence of cal signals from a mechanical stimulus) also
each disease (which is unknown). Regardless of the ex- confer a predisposition to IPF.18,19
act prevalence of each condition, idiopathic pulmonary
A single-nucleotide polymorphism (rs35705950)
fibrosis, chronic hypersensitivity pneumonitis, connec-
tive-tissue disease–related ILD (CTD-ILD), and pulmo- in the promoter region of MUC5B substantially
nary sarcoidosis are the most common interstitial lung increases the risk of IPF.20 MUC5B codes for mu-
diseases seen in our clinical practices. cin 5B, a glycoprotein required for airway clear-
ance and innate immune responses to bacteria.21
1812 n engl j med 378;19 nejm.org May 10, 2018

Table 1. Clinical Presentation of Idiopathic Pulmonary

Animal models of lung fibrosis do not reca-
Fibrosis (IPF).* pitulate IPF. Nevertheless, these models have been
useful for identifying pathways leading to lung
History fibrosis, including those involving transforming
Chronic exertional dyspnea (nearly universal)† growth factor β (TGF-β), connective-tissue growth
Chronic cough without purulence factor, fibroblast growth factor 2, platelet-derived
Fatigue growth factor, microRNAs, impaired autophagy,
Physical examination activation of developmental pathways, matrix
Bilateral Velcro-like crackles† metalloproteinase 7 (MMP-7), lysyl oxidase–like 2
Clubbing
(LOXL2), and lysophosphatidic acid (LPA) (Fig. 2).
Mechanical contributions of the matrix to cell
Acrocyanosis
behavior (e.g., matrix stiffness and stress and
Physiological findings
strain forces) have also been highlighted.31
Low DLco† A number of nongenetic risk factors for IPF
Resting hypoxemia or exertional desaturation have been identified. Older age, male sex, and
Normal or low FVC cigarette smoking are considered risk factors for
Chest radiograph IPF.32 Observational data have implicated gastro-
Nonspecific changes or bilateral basal reticular abnormalities esophageal reflux,33 obstructive sleep apnea,34 air
pollution,35 herpesvirus infection,36 and certain
* DLco denotes diffusing capacity of the lung for carbon occupational exposures in interstitial lung dis-
monoxide, and FVC forced vital capacity.
† This finding is nearly universal in IPF. Other findings are ease.32 The investigation of subclinical disease
often absent in the early stages of the disease. with the use of computed tomographic (CT)
imaging in population-based and high-risk co-
horts has proved to be a powerful tool that may
The rs35705950 minor allele leads to overexpres- help identify new targetable risk factors for inci-
sion of mucin 5B in small-airway epithelial dent IPF, potentially leading to preventive inter-
cells,22 a universal finding in patients with IPF ventions.37-40
(regardless of the MUC5B genotype).20 Although
the mechanism linking mucin 5B overexpression Di agnosis
and IPF risk remains unknown, some research-
ers have hypothesized that aberrant mucociliary When the history and physical examination sug-
clearance may lead to alterations in the lung gest interstitial lung disease, a high-resolution CT
microbiome and innate immune responses that scan of the chest should be obtained to determine
promote IPF.23,24 whether the disease is present and to identify
Indeed, innate immune cells, such as mono- specific radiologic patterns that aid in narrowing
cyte-derived alveolar macrophages, appear to be the differential diagnosis.2 High-resolution CT
critical for the development of lung fibrosis.25 In protocols should include both inspiratory and ex-
one study, bacterial DNA could not be detected piratory imaging, thin reconstructions (≤1.25 mm),
in lung tissue from patients with IPF,26 but other a moderately sharp reconstruction kernel, and a
work has identified an abundance of prevotella, small reconstruction field of view. Although in-
veillonella, and escherichia in bronchoalveolar- spiratory imaging should be contiguous, expira-
lavage fluid from such patients. In addition, both tory imaging can be noncontiguous to minimize
an increased overall bacterial burden and an abun- radiation exposure. Imaging with the patient in
dance of streptococcal and staphylococcal organ- the prone position should be performed only if
isms have been associated with an increased risk there are subtle dependent opacities of unclear
of disease progression in patients with IPF.27,28 clinical significance.
Additional elegant microbiome work29 and the Once interstitial lung disease has been identi-
finding that the risk of IPF is increased by genetic fied on high-resolution CT studies, a focused
variation in TOLLIP, a gene encoding a protein in history taking and physical examination should
the toll-like receptor pathway that inhibits respons- be performed to identify disorders that are
es to microbes,30 suggest a complex relation- known to cause interstitial lung disease, such as
ship among IPF risk, microbiome diversity, host chronic hypersensitivity pneumonitis, or to be
defense pathways, and disease progression.23,29 associated with it, such as connective-tissue dis-

A B C
Environmental Risk Factors

Smoking
Microaspiration
Occupational exposures
Viral infection
Abnormal *
mucociliary
Mechanical strain clearance
Air pollution
Low Power High Power
Airway epithelial cells
Increased mucin 5b Latent TGF-β

expression Macrophage PDGF
CCL2 Galectin-3
(MUC5B promoter SNP) PRM-151
(MCP-1) MMPs
Antimicrobials (pentraxin-2)
Type I alveolar
epithelial cells CCR2
Type II alveolar Microbiome diversity

epithelial cells and bacterial burden
Matrix turnover
MMP-7
Other MMPs
Epithelial cell A LV E OLUS TIMPs
injury Myofibroblasts
Collagen cross-linking
Senescent
Type II Cell LOXL2
Apoptotic
type II cell
Fibroblast
Tyrosine Kinase and G-Protein–Coupled Multiple Mechanisms

Serine–Threonine Kinase Pathways Pathway
FGF-2 VEGF PDGF Active
LPC GLPG1690 Pirfenidone
TGF-β
TGFBR1 Autotaxin
CTGF and LPA PBI-4050
Endoplasmic FGFR1 VEGFR PDGFR BMS-986020
CXCL12 (SDF-1) TGFBR2
reticulum Pamrevlumab
MMPs
stress
PDGF LPA 1 CTGF
Latent TGF-β
Apoptosis and TD139
cellular senescence
Galectin-3
Active
Shortened Mitochondrial TGF-β
telomeres dysfunction and αVβ6 Nintedanib
impaired integrin Myofibroblast differentiation
mitophagy Matrix deposition
Fibroblast proliferation
Cell adhesion BG00011 and reduced apoptosis
abnormalities Senescence-associated secretory phenotype
TRPV4
Down-regulation of miR-29
Impaired autophagy
Extracellular matrix stiffness
F I B RO B L A S T
and mechanical signaling

CCP, anti-Ro, anti-La, anti-

Figure 2 (facing page). Pathobiologic Features
ANA; rheumatoid factor; anti-

Peribronchovascular distri- Hypersensitivity pneumonitis
antibodies; CK; myoglobin
Lymphocyte-proliferation test
of Idiopathic Pulmonary Fibrosis.
panel in selected cases
U1RNP, and anti-Jo-1

Serologic Testing
Panel A shows a conceptual model of the pathobiology
of idiopathic pulmonary fibrosis, which is characterized
None
by recurrent epithelial-cell injury, senescent alveolar
for berylliosis
epithelial cells, profibrotic mediators leading to matrix
deposition by myofibroblasts, microbiome changes,
and host defense abnormalities. Potential therapeutic
interventions are shown in green. Histologic features
of usual interstitial pneumonia are shown in Panels B
and C at low magnification and high magnification, re-
bution, mosaic ground-
ground-glass opacities
spectively (hematoxylin and eosin). The photomicro-
piratory gas trapping,
sive massive fibrosis,

Pleural plaques, progres-
glass attenuation, ex
Synovitis, joint deformities, Ground-glass opacities,

pleural involvement
Ground-glass opacities
graphs show a marked patchy fibrosis in a peripheral,
lobular (paraseptal) distribution. Fibroblastic foci (aster-
HRCT
isk) are typically a prominent (but nonspecific) feature.
Findings Inconsistent with IPF†
* ANA denotes antinuclear antibodies, anti-CCP anti–cyclic citrullinated peptide antibodies, CK creatine kinase, and HRCT high-resolution CT.
Notably absent are features that would suggest an alter-
nodules
native interstitial lung disease, such as granulomas,
hyaline membranes, organizing pneumonia, and marked
inflammation. AEC denotes alveolar epithelial cell,
CTGF connective-tissue growth factor, CCL2 chemo-
kine (C-C motif) ligand 2, CCR2 chemokine (C-C motif)
† Crackles are noted on lung examination in nearly all cases. Reticulation with or without traction bronchiectasis is common.
sclerodactyly, mechan-
rheumatoid nodules,
ic’s hands, Gottron’s

receptor 2, CXCL12 C-X-C motif chemokine ligand 12,
Inspiratory squeaks
papules, Raynaud’s
FGF-2 fibroblast growth factor 2, FGFR1 fibroblast
growth factor receptor 1, LOXL2 lysyl oxidase–like 2,
Physical
phenomenon
None
None
LPA lysophosphatidic acid, LPA1 lysophosphatidic acid
receptor type 1, LPC lysophosphatidylcholine, MCP-1
monocyte chemoattractant protein 1, MMP matrix
metalloproteinase, PDGF platelet-derived growth factor,
PDGFR platelet-derived growth factor receptor, SDF-1
stromal-cell–derived factor 1, TGF-β transforming
or visible mold; indoor or caged
Microbes in the home or workplace
from forced-air heating, humid-
birds, down or feather bedding,

ifiers, hot tubs, water damage,
growth factor β, TGFBR1 TGF-β receptor type 1, TIMP
Clues from the Patient History
skin thickening or tightening;

Joint pain, stiffness, or swelling;
Occupational history and expo-

tissue inhibitor of metalloproteinases, TRPV4 transient
rash; dry eyes; dry mouth;
or tenderness; Raynaud’s
receptor potential cation channel subfamily V member 4,
Medication history
heartburn; muscle pain
agricultural exposure
VEGF vascular endothelial growth factor, and VEGFR

Table 2. Fibrotic Interstitial Lung Diseases (ILDs) of Known Cause That Mimic IPF.*
vascular endothelial growth factor receptor.
ease (Table 2), which are more common in phenomenon

younger and middle-age adults with interstitial
sures
lung disease. We routinely question patients
about exposure to dampness, mold, or birds in
the home or workplace, which can cause chron-
Amiodarone, methotrexate, nitro-
furantoin, chemotherapeutic
(specific exposures are often
matory myopathy (e.g., anti-

sclerosis, idiopathic inflam-
Rheumatoid arthritis, systemic
ic hypersensitivity pneumonitis. We also look for pneumoconiosis, silicosis,

mycobacteria, isocyanates
Examples or Causes
synthetase syndrome),
signs and symptoms of autoimmune conditions,

Asbestosis, coal workers’
Sjögren’s syndrome
and we routinely test for antinuclear antibodies;

Chronic hypersensitivity Mold, avian antigens,
not identifiable)
rheumatoid factor; anti–cyclic citrullinated pep-

tide antibodies; antibodies against Scl-70, Ro, La,
berylliosis
U1-RNP, and Jo-1; creatine kinase; and myoglo-

agents
bin. In selected cases, a more extensive panel of

antisynthetase antibodies should be considered.
However, the presence of autoantibodies is not
disease–related ILDs
Pneumoconiosis (occu-
sufficient to rule out IPF. Input from a rheuma-

tologist should be sought when the history,
Drug-induced ILDs
pational ILDs)
Connective-tissue
pneumonitis
physical examination, or serologic testing sug-

gests autoimmune disease.
Condition
If no cause can be identified, IPF should be

included in the differential diagnosis, particularly
for patients who are more than 50 years of age.

The findings on high-resolution CT can be used Figure 3 (facing page). High-Resolution CT Images
to infer whether the histologic pattern of IPF is of the Chest Showing Various ILD Patterns.
present, thereby obviating the need for a lung Panels A, B, and C show the pattern of usual interstitial
biopsy in some cases. This pattern, termed pneumonia (UIP): predominant peripheral and lower-
“usual interstitial pneumonia” (UIP), consists of lobe reticulation (blue arrows) and honeycombing
heterogeneous paraseptal fibrosis with architec- ( yellow arrows), as well as traction bronchiectasis
(green arrow). This pattern is diagnostic of idiopathic
tural distortion (Fig. 2). The term UIP is also pulmonary fibrosis if no known cause is identified.
used to describe a high-resolution CT pattern Panels D, E, and F show features of “probable UIP”:
characterized by bilateral reticulation and honey- predominant peripheral and lower-lobe reticulation
combing that is predominantly peripheral and in (blue arrows) and traction bronchiectasis (green arrow)
the lower lobes (Fig. 3A, 3B, and 3C), which has without honeycombing. A probable UIP pattern with
substantial bronchiectasis, reticulation, or both in older
a high positive predictive value for a histologic adults strongly supports a diagnosis of IPF if no known
UIP pattern. Therefore, if no cause is identified, cause of ILD is identified. Panels G, H, and I show CT
a typical UIP pattern on high-resolution CT is features that are most consistent with a non-IPF diag-
diagnostic of IPF. nosis: a predominance of ground-glass opacities (black
A “probable UIP” pattern on high-resolution arrows) and reticular abnormalities in the lower lung,
with subpleural sparing. Although not diagnostic, this
CT, defined as bilateral reticulation that is pre- pattern is commonly seen when a histologic pattern of
dominantly peripheral and in the lower lobes, nonspecific interstitial pneumonia is present. Panels J,
with traction bronchiectasis but without honey- K, and L show CT features that are highly suggestive of
combing (Fig. 3D, 3E, and 3F), is also suggestive hypersensitivity pneumonitis: sharply defined mosaic
of an underlying histologic UIP pattern.41 In attenuation and ground-glass opacities (black arrows)
with mild reticulation. Images are shown from left to
studies performed at tertiary care centers with right as axial, coronal, and sagittal reconstructions.
multidisciplinary discussions used for diagnosis,
a probable UIP pattern on high-resolution CT
was diagnostic of IPF in older adults who had The procedure should not be performed in high-
substantial traction bronchiectasis or reticula- risk patients, including those with high oxygen
tion.42,43 IPF may therefore also be confidently requirements (e.g., >2 liters per minute), pulmo-
diagnosed on the basis of these findings, with- nary hypertension, rapid disease progression,
out the need for a lung biopsy. severely reduced FVC or DLco, multiple coexist-
Atypical features on high-resolution CT, including conditions, or frailty.44 Transbronchial lung
ing upper-lung or midlung predominance, peri- cryobiopsy has been increasingly advocated as a
bronchovascular predominance, subpleural sparing replacement for thoracoscopic biopsy. Although
(Fig. 3G, 3H, and 3I), predominant consolidation, experience with this technique is growing, cur-
extensive ground-glass opacities, extensive mo- rent data do not support its use.45-48 Surgical bi-
saic attenuation (Fig. 3J, 3K, and 3L), and diffuse opsy remains the standard procedure for obtain-
nodules or cysts, should raise suspicion of an ing lung tissue to establish a diagnosis of
interstitial lung disease other than IPF.41 Identify- interstitial lung disease.
ing these features can be difficult, and referral If a histologic UIP pattern is found in the
to a center that specializes in interstitial lung absence of a known cause, IPF can often be con-
disease may help establish an accurate diagnosis fidently diagnosed.41 In other circumstances,
without a lung biopsy. despite the availability of extensive clinical data,
When the combination of clinical and imag- confirmation of the diagnosis remains challeng-
ing data is not diagnostic, a thoracoscopic lung ing, particularly for nonexpert clinicians.49 Face-
biopsy can be considered if the results are ex- to-face multidisciplinary discussions involving
pected to influence therapy. Biopsy samples clinicians, radiologists, and pathologists are now
should be taken from multiple lobes, and sur- widely used to increase diagnostic agreement.50
geons should avoid sampling the most severely The reproducibility of an IPF diagnosis estab-
affected areas, since samples from these areas lished by multidisciplinary discussion is good
typically show advanced, nondiagnostic fibrosis. and improves prognostication.51

A B C
D E F
G H I
J K L

Table 3. Pharmacologic Management of IPF.*
Variable Nintedanib Pirfenidone

Mechanism of action Tyrosine kinase inhibition Inhibition of TGF-β production and downstream
signaling, collagen synthesis, and fibroblast
proliferation (selected list)
Efficacy Slows FVC decline by 50% Slows FVC decline by 50%
FDA-approved dose 150 mg by mouth twice daily 801 mg by mouth thrice daily
Common side effects Diarrhea Anorexia, nausea, photosensitivity
Enzyme metabolism Ester cleavage (major), CYP 3A4 (minor) CYP 1A2 (major), other CYP enzymes (minor)
Cautions Risks of both bleeding and arterial thrombo- CYP 1A2 inhibitors (e.g., fluvoxamine and
sis; risk of gastrointestinal perforation ciprofloxacin) can raise pirfenidone levels;
(rare); anticoagulant and prothrombotic CYP 1A2 inducers (e.g., omeprazole and
drugs should be avoided smoking) can lower pirfenidone levels
Need for liver-function monitoring Yes† Yes‡
Clinical strategies to minimize side effects Use of antidiarrheal agents, temporary dose Slow dose increase over 14-day period, medica-
reduction to 100 mg twice daily tion to be taken with food, use of antacids,
use of antiemetic agents, sun avoidance
* Nonpharmacologic management includes smoking cessation, age-appropriate vaccination, supplemental oxygen, pulmonary rehabilitation,
evaluation for lung transplantation, diagnosis and management of depression and anxiety, weight and nutrition management, and support
and education. CYP denotes cytochrome P450, FDA Food and Drug Administration, and TGF-β transforming growth factor β.
† Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin should be measured before the start of treatment, monthly
for the first 3 months of treatment, and then as clinically indicated. Nintedanib should be discontinued when the AST or ALT level is more
than 3 times the upper limit of the normal range if there is clinical evidence of hepatic dysfunction or the bilirubin level exceeds the upper
limit of the normal range. If no clinical signs or symptoms are present, an AST or ALT level that is 3 to 5 times the upper limit of the normal
range should prompt a reduction in the dose to 100 mg twice daily and additional evaluation as clinically indicated. An AST or ALT level that
is more than 5 times the upper limit of the normal range should always prompt discontinuation of nintedanib, regardless of whether there
are clinical signs or symptoms of hepatic dysfunction. Liver function should be closely monitored until the levels return to baseline values.
‡ AST, ALT, and bilirubin should be measured before the start of treatment, monthly for the first 6 months of treatment, and then every 3 months.
Pirfenidone should be permanently discontinued when the AST or ALT level is more than 3 times the upper limit of the normal range if there is
clinical evidence of hepatic dysfunction or the bilirubin level exceeds the upper limit of the normal range. If no clinical signs or symptoms
are present, an AST or ALT level that is 3 to 5 times the upper limit of the normal range should prompt careful monitoring of liver function
and additional evaluation as clinically indicated. An AST or ALT level that is more than 5 times the upper limit of the normal range should
always prompt discontinuation of pirfenidone, regardless of whether there are clinical signs or symptoms of hepatic dysfunction.
Molecular diagnostic markers, including cir- cannot be overemphasized. Smoking cessation

culating matrix metalloproteinases,52 combina- should be a priority for patients who are actively
tions of circulating proteins,53 and a peripheral- using tobacco products. Influenza, pneumococ-
blood transcriptomic signature,54 have been cal, and other age-appropriate vaccines should
explored because of the diagnostic challenge. be administered.
A gene-expression signature developed with the
use of a machine-learning approach has been Supplemental Oxygen
applied to surgical lung-biopsy samples to en- Clinical practice guidelines strongly recommend
hance the identification of a UIP pattern55; this supplemental oxygen for patients with IPF.2 Oxy-
approach has been extended to transbronchial gen administration reduces exertional dyspnea
lung-biopsy samples.56 It remains unclear how and improves exercise tolerance.57 An oxyhemo-
such molecular approaches will be integrated globin saturation of 88% or less at rest, during
into clinical practice, and their use cannot be exertion, or during sleep should prompt initia-
recommended until further data are available. tion of home oxygen therapy. The oxygen pre-
scription should be informed by 6-minute walk
tests or treadmill testing of oxygen saturation,
Nonph a r m ac ol o gic M a nagemen t
as well as by nocturnal oximetry or polysomnog-
Nonpharmacologic management strategies help raphy when indicated (see Table S1 in the Sup-
patients with IPF live healthier, more normal plementary Appendix, available with the full text
lives, and the importance of these approaches of this article at NEJM.org).

Pulmonary Rehabilitation factor receptors 1, 2, and 3, and platelet-derived

Pulmonary rehabilitation, a structured exercise growth factor receptor (Fig. 2). Patients should
program designed for adults with advanced lung initially be prescribed 150 mg of nintedanib, to
disease, has been shown to improve exercise be taken by mouth twice daily. The medication
capacity and health-related quality of life for should be taken with food and can be continued
patients with IPF.58 indefinitely. Patients taking nintedanib common-
ly have diarrhea, which can often be managed
Lung Transplantation with antidiarrheal agents.64 The dose can be
More than 2000 lung transplantations are per- decreased to 100 mg twice daily if unmanage-
formed in the United States each year, approxi- able side effects occur. Cases of drug-induced
mately half of which are performed for intersti- liver injury have been reported. Liver function
tial lung disease.59 Thus, only a minority of should be tested at baseline, monitored monthly
patients with IPF receive a transplant. Lung for the first 3 months, and then monitored as
transplantation can prolong survival and im- clinically indicated. Since nintedanib is associat-
prove quality of life for highly selected candi- ed with a small increase in the risk of bleeding,
dates60,61; however, only 66% of transplant re- this agent should be used with great caution, if at
cipients with IPF survive for more than 3 years all, in patients receiving full-dose anticoagulant
after transplantation and only 53% survive for therapy. Atheroembolic events, including myo-
more than 5 years.59 Common complications in- cardial infarction, have also been reported with
clude primary graft dysfunction, acute and chron- nintedanib.64 Caution should be used when treat-
ic forms of allograft rejection, cytomegaloviral ing patients with cardiovascular risk factors, in-
and other infections, and cancer.59 IPF has not cluding those who have coronary artery disease.
been shown to recur in the allograft. Referral to Pirfenidone has a number of antiinflamma-
a transplantation center should be made at the tory and antifibrotic effects, including inhibition
time of diagnosis, since the evaluation process of collagen synthesis, down-regulation of TGF-β
and waiting time can last for months to years.62 and tumor necrosis factor alpha, and a reduction
Common contraindications include recent can- in fibroblast proliferation.70 Pirfenidone is pre-
cer, advanced nonpulmonary organ failure, and scribed in an escalating-dose fashion over a 14-
lack of a reliable social support system.62 day period: 267 mg (one capsule) by mouth three
times daily for 1 week, 534 mg (two capsules)
three times daily for 1 week, and 801 mg (three
Ph a r m ac ol o gic M a nagemen t
capsules) three times daily thereafter. Patients
During the past 5 years, notable advances have can subsequently be transitioned to an 801-mg
been made in pharmacotherapeutic approaches tablet three times daily. Pirfenidone must be
to IPF.63 Two medications, nintedanib and pir- taken with food and can be continued indefi-
fenidone, have been shown to be safe and effec- nitely. Common side effects, such as anorexia,
tive in the treatment of IPF; both are recom- nausea, and vomiting,65 can often be ameliorated
mended for use in patients with IPF (Table 3).63 by judicious use of antacids and antiemetic
In placebo-controlled, randomized trials, each agents. In some cases, side effects are severe
drug has been shown to slow the rate of FVC enough to require a lower total daily dose (six to
decline by approximately 50% over the course eight capsules daily). A photosensitive rash can
of 1 year.64,65 Both have shown some efficacy in also occur. Liver function should be monitored
reducing severe respiratory events, such as acute periodically.
exacerbations, and hospitalization for respiratory It is difficult to recommend one agent over
events.66,67 Pooled data and meta-analyses sug- the other, since there have been no head-to-head
gest that these agents may reduce mortality.68,69 comparisons. A network meta-analysis concluded
The cost of each medication is estimated to ex- that pirfenidone and nintedanib provide similar
ceed $100,000 annually. benefits.71,72 No data are available to guide clini-
Nintedanib is a tyrosine kinase inhibitor that cians regarding the timing of initiation of ther-
targets growth factor pathways, including those apy, how a response should be defined, and when
downstream from vascular endothelial growth the therapy should be discontinued.73 Recent
factor receptors 1, 2, and 3, fibroblast growth data on treatment that combines these agents

suggest clinically significant gastrointestinal side biome in IPF are ongoing (NCT02759120; and
effects.74 EudraCT number, 2014-004058-32).
Treatment guidelines for IPF include a strong There are several possible approaches for the
recommendation against the use of predni- management of cough in IPF, though none are
sone in combination with azathioprine and oral universally effective. A trial of thalidomide con-
N-acetylcysteine, a regimen associated with an firmed that it could be used to ameliorate cough
increase in mortality by a factor of 9, as com- in patients with IPF.89 An observational study
pared with placebo.10 A clinical trial showed no suggests that pirfenidone may attenuate cough.90
effect of N-acetylcysteine monotherapy on lung The P2X3 antagonist AF-219/MK-7264 (gefapixant)
function.75,76 Interferon-γ,77 endothelin antago- suppresses idiopathic cough91; a trial of this
nists,78 and warfarin79 are ineffective or harmful agent in patients with IPF has been completed
in patients with IPF. The Food and Drug Admin- (NCT02502097). Finally, an inhaled cromolyn
istration has appropriately warned consumers preparation was shown to ameliorate cough in
against various unapproved stem-cell “therapies” patients with IPF.92
advertised for the treatment of IPF.80
Although current guidelines recommend the C ompl ic at ions a nd Mor ta l i t y
use of antacid therapy to treat IPF,63 there are no
data from clinical trials to support this recom- IPF carries a poor prognosis, with a median
mendation. In two studies, antacid use was as- survival of 3.8 years among adults 65 years of
sociated with a slower decline in lung function age or older in the United States.6 Although this
and a lower mortality rate.81,82 These observa- statistic is disappointing, in practice it is not
tional studies of treatment effect are, by nature, uncommon for patients to live 5 years or more
confounded by indication and should not be used after receiving the diagnosis. Many patients die
to inform clinical practice.83 More recent data sug- from progressive, chronic hypoxemic respiratory
gest that antacid therapy may increase the risk failure. Palliative care is rarely instituted in pa-
of respiratory infections in patients with IPF.84 tients with IPF before the end of life.93
Growing knowledge of the biologic underpin- Each year, approximately 10 to 20% of patients
nings of fibroproliferation has opened new thera- with IPF have an acute exacerbation, characterized
peutic avenues. A phase 2 trial of pamrevlumab, by worsened hypoxemic respiratory failure, with
an intravenously administered antibody targeting bilateral ground-glass opacities, consolidation, or
connective-tissue growth factor, slowed the de- both on high-resolution CT imaging that are not
cline in FVC, as compared with placebo, over a fully explained by volume overload.94 Exacerba-
period of 48 weeks.85 PBI-4050, which targets tions may be triggered by a clinical event (e.g.,
multiple profibrotic cytokines and alters fibro- infection, aspiration, or drug toxicity) but are
blast function,70 may improve FVC when admin- frequently idiopathic.94 Most patients with an
istered in combination with nintedanib.86 TD139, acute exacerbation die from acute respiratory
an inhaled galectin-3 inhibitor, has been shown failure. Available guidelines make weak recom-
to lower galectin-3 expression on alveolar macro- mendations for the use of glucocorticoids and
phages in IPF.87 GLPG1690, which targets auto- do not recommend the use of mechanical venti-
taxin, an enzyme responsible for LPA produc- lation in patients with an acute exacerbation,
tion, may reduce circulating LPA levels while emphasizing the need to establish physician or-
influencing lung function and findings on func- ders regarding life-sustaining treatment before
tional respiratory imaging. Trials of BMS-986020 the onset of a life-threatening event.2
(ClinicalTrials.gov number, NCT01766817), an oral Patients with IPF are at increased risk for ve-
LPA antagonist, and BG00011 (NCT01371305), nous thromboembolism,95 lung cancer,96 and pul-
a monoclonal antibody targeting the αVβ6 inte- monary hypertension.97 A high index of suspicion
grin, have been completed, and the results are should be maintained for pulmonary embolism
pending. A phase 1 study has shown that PRM- as the cause of any acute respiratory deteriora-
151 (recombinant pentraxin-2) is safe in patients tion. Incidental pulmonary nodules should be
with IPF88; a phase 2 study (NCT02550873) has managed according to established guidelines for
been completed. Two clinical trials of antimicro- high-risk patients.98 Annual low-dose CT scan-
bial therapy potentially targeting the lung micro- ning should be considered for patients meeting

the U.S. Preventive Services Task Force criteria Dr. Lederer reports receiving consulting fees, advisory board
fees, and fees for serving on a steering committee from Genen-
for lung-cancer screening.99 Although pulmonary tech/Roche, grant support and advisory board fees from Boeh-
hypertension occurs in some patients with IPF, ringer Ingelheim, consulting fees and advisory board fees from
management in the outpatient setting should Veracyte, fees for serving on an adjudication committee from
Degge Group, lecture fees, fees for serving on a steering com-
consist solely of supplemental oxygen, without mittee, and fees for generation of educational content from
pulmonary vasodilator therapy. Until further data France Foundation, grant support and consulting fees from Fi-
are available, targeted therapies approved for pul- brogen and Global Blood Therapeutics, and consulting fees
from Patara, Philips Respironics, ImmuneWorks, Sanofi Gen-
monary arterial hypertension should be avoided zyme, and Galapagos; and Dr. Martinez, receiving honoraria
in patients with IPF unless they are enrolled in a and travel support from AstraZeneca, Continuing Education,
clinical trial investigating such therapies.100 ConCert, Inova Fairfax Health System, MD Magazine, Miller
Communications, National Association for Continuing Educa-
tion, Novartis, Pearl Pharmaceuticals, PeerView Communications,
Prime Communications, Puerto Rican Respiratory Society, Po-
F u t ur e Dir ec t ions tomac, Chiesi, Roche, Sunovion, Theravance, and University of
Alabama Birmingham, receiving advisory board fees and travel
In light of the rising prevalence of IPF and the support and serving on a data and safety monitoring board for
increase in associated mortality, we hope that Boehringer Ingelheim, Genentech, and GlaxoSmithKline, serv-
the next 5 years will be marked by greater rec- ing on the chronic obstructive pulmonary disease advisory board
for ProterixBio, receiving honoraria from Columbia University,
ognition of the disease on the part of primary Haymarket Communications, Integritas, Inthought Research,
care providers, leading to earlier involvement of Methodist Hospital Brooklyn, New York University, Unity, UpTo-
a multidisciplinary team to aid in diagnosis and Date, WedMD/MedScape, Western Connecticut Health Network,
Academic CME, Clarion, Patara, PeerView, and PlatformIQ,
management. Novel preventive interventions, serving on the Idiopathic Pulmonary Fibrosis (IPF) Study steer-
evolving use of screening biomarkers, and the ing committee for Afferent, Gilead, and Veracyte, serving on the
eventual ability to target newly discovered risk pulmonary hypertension–idiopathic interstitial pneumonias
(PH-IIP) study steering committee for Bayer, serving on the IPF
factors for IPF could lead to a decline in the in- Study data and safety monitoring board for Stromedix/Biogen,
cidence of this disease as well as other fibrotic and receiving travel support from Nitto and Zambon. No other
interstitial lung diseases in coming years. Ad- potential conflict of interest relevant to this article was reported.
Disclosure forms provided by the authors are available with
vances in therapeutics, including individualized the full text of this article at NEJM.org.
approaches and interventions to halt collagen We thank Drs. Gisli Jenkins and Naftali Kaminski for their
deposition, may one day eliminate the need for advice and comments about the mechanisms underlying idio-
pathic pulmonary fibrosis, Dr. David Lynch for his review of
lung transplantation and turn IPF into a lifelong findings on high-resolution CT studies, and Dr. Alain Borczuk
chronic disease. for providing histologic images.
References
1. Rosas IO, Dellaripa PF, Lederer DJ, 6. Raghu G, Chen SY, Yeh WS, et al. Idio- Nintedanib in patients with idiopathic
Khanna D, Young LR, Martinez FJ. Inter- pathic pulmonary fibrosis in US Medicare pulmonary fibrosis and preserved lung
stitial lung disease: NHLBI Workshop on beneficiaries aged 65 years and older: in- volume. Thorax 2017;72:340-6.
the Primary Prevention of Chronic Lung cidence, prevalence, and survival, 2001-11. 12. Albera C, Costabel U, Fagan EA, et al.
Diseases. Ann Am Thorac Soc 2014;11: Lancet Respir Med 2014;2:566-72. Efficacy of pirfenidone in patients with
Suppl 3:S169-S177. 7. Hutchinson JP, McKeever TM, Fogarty idiopathic pulmonary fibrosis with more
2. Raghu G, Collard HR, Egan JJ, et al. AW, Navaratnam V, Hubbard RB. Increas- preserved lung function. Eur Respir J 2016;
An official ATS/ERS/JRS/ALAT statement: ing global mortality from idiopathic pul- 48:843-51.
idiopathic pulmonary fibrosis: evidence- monary fibrosis in the twenty-first century. 13. Cottin V, Hansell DM, Sverzellati N,
based guidelines for diagnosis and man- Ann Am Thorac Soc 2014;11:1176-85. et al. Effect of emphysema extent on serial
agement. Am J Respir Crit Care Med 2011; 8. Navaratnam V, Fogarty AW, Glendening lung function in patients with idiopathic
183:788-824. R, McKeever T, Hubbard RB. The increas- pulmonary fibrosis. Am J Respir Crit Care
3. Hutchinson J, Fogarty A, Hubbard R, ing secondary care burden of idiopathic Med 2017;196:1162-71.
McKeever T. Global incidence and mortal- pulmonary fibrosis: hospital admission 14. Selman M, Pardo A. Revealing the
ity of idiopathic pulmonary fibrosis: a sys- trends in England from 1998 to 2010. pathogenic and aging-related mechanisms
tematic review. Eur Respir J 2015;46:795- Chest 2013;143:1078-84. of the enigmatic idiopathic pulmonary
806. 9. Hewson T, McKeever TM, Gibson JE, fibrosis. an integral model. Am J Respir
4. Esposito DB, Lanes S, Donneyong M, Navaratnam V, Hubbard RB, Hutchinson Crit Care Med 2014;189:1161-72.
et al. Idiopathic pulmonary fibrosis in JP. Timing of onset of symptoms in people 15. Alder JK, Chen JJ, Lancaster L, et al.
United States automated claims: incidence, with idiopathic pulmonary fibrosis. Thorax Short telomeres are a risk factor for idio-
prevalence, and algorithm validation. Am 2017 October 11 (Epub ahead of print). pathic pulmonary fibrosis. Proc Natl Acad
J Respir Crit Care Med 2015;192:1200-7. 10. The Idiopathic Pulmonary Fibrosis Sci U S A 2008;105:13051-6.
5. Raghu G, Chen SY, Hou Q, Yeh WS, Clinical Research Network. Prednisone, 16. Armanios MY, Chen JJ-L, Cogan JD,
Collard HR. Incidence and prevalence of azathioprine, and N-acetylcysteine for et al. Telomerase mutations in families
idiopathic pulmonary fibrosis in US adults pulmonary fibrosis. N Engl J Med 2012; with idiopathic pulmonary fibrosis. N Engl
18-64 years old. Eur Respir J 2016;48:179- 366:1968-77. J Med 2007;356:1317-26.
86. 11. Kolb M, Richeldi L, Behr J, et al. 17. Tsakiri KD, Cronkhite JT, Kuan PJ, et al.

Adult-onset pulmonary fibrosis caused by 32. Baumgartner KB, Samet JM, Coultas plications of transbronchial lung cryo
mutations in telomerase. Proc Natl Acad DB, et al. Occupational and environmen- biopsy for interstitial lung disease: a sys-
Sci U S A 2007;104:7552-7. tal risk factors for idiopathic pulmonary tematic review and metaanalysis. Ann Am
18. Fingerlin TE, Murphy E, Zhang W, et al. fibrosis: a multicenter case-control study. Thorac Soc 2016;13:1828-38.
Genome-wide association study identifies Am J Epidemiol 2000;152:307-15. 46. Tomassetti S, Wells AU, Costabel U,
multiple susceptibility loci for pulmonary 33. Tobin RW, Pope CE II, Pellegrini CA, et al. Bronchoscopic lung cryobiopsy in-
fibrosis. Nat Genet 2013;45:613-20. Emond MJ, Sillery J, Raghu G. Increased creases diagnostic confidence in the multi-
19. Allen RJ, Porte J, Braybrooke R, et al. prevalence of gastroesophageal reflux in disciplinary diagnosis of idiopathic pul-
Genetic variants associated with suscepti- patients with idiopathic pulmonary fibro- monary fibrosis. Am J Respir Crit Care
bility to idiopathic pulmonary fibrosis in sis. Am J Respir Crit Care Med 1998;158: Med 2016;193:745-52.
people of European ancestry: a genome- 1804-8. 47. DiBardino DM, Haas AR, Lanfranco
wide association study. Lancet Respir Med 34. Kim JS, Podolanczuk AJ, Borker P, AR, Litzky LA, Sterman D, Bessich JL.
2017;5:869-80. et al. Obstructive sleep apnea and subclini- High complication rate after introduction
20. Seibold MA, Wise AL, Speer MC, et al. cal interstitial lung disease in the Multi- of transbronchial cryobiopsy into clinical
A common MUC5B promoter polymor- Ethnic Study of Atherosclerosis (MESA). practice at an academic medical center.
phism and pulmonary fibrosis. N Engl J Ann Am Thorac Soc 2017;14:1786-95. Ann Am Thorac Soc 2017;14:851-7.
Med 2011;364:1503-12. 35. Sack C, Vedal S, Sheppard L, et al. Air 48. Patel NM, Borczuk AC, Lederer DJ.
21. Roy MG, Livraghi-Butrico A, Fletcher pollution and subclinical interstitial lung Cryobiopsy in the diagnosis of interstitial
AA, et al. Muc5b is required for airway disease: the Multi-Ethnic Study of Athero- lung disease: a step forward or back? Am
defence. Nature 2014;505:412-6. sclerosis (MESA) air-lung study. Eur Respir J J Respir Crit Care Med 2016;193:707-9.
22. Nakano Y, Yang IV, Walts AD, et al. 2017;50(6):1700559. 49. Walsh SLF, Maher TM, Kolb M, et al.
MUC5B promoter variant rs35705950 af- 36. Tang Y-W, Johnson JE, Browning PJ, Diagnostic accuracy of a clinical diagnosis
fects MUC5B expression in the distal air- et al. Herpesvirus DNA is consistently de- of idiopathic pulmonary fibrosis: an inter-
ways in idiopathic pulmonary fibrosis. tected in lungs of patients with idiopathic national case-cohort study. Eur Respir J
Am J Respir Crit Care Med 2016;193:464-6. pulmonary fibrosis. J Clin Microbiol 2003; 2017;50(2):1700936.
23. Molyneaux PL, Willis-Owen SAG, Cox 41:2633-40. 50. Flaherty KR, King TE Jr, Raghu G,
MJ, et al. Host-microbial interactions in 37. Podolanczuk AJ, Oelsner EC, Barr RG, et al. Idiopathic interstitial pneumonia:
idiopathic pulmonary fibrosis. Am J Respir et al. High attenuation areas on chest com- what is the effect of a multidisciplinary
Crit Care Med 2017;195:1640-50. puted tomography in community-dwelling approach to diagnosis? Am J Respir Crit
24. Morris A, Gibson K, Collman RG. The adults: the MESA study. Eur Respir J 2016; Care Med 2004;170:904-10.
lung microbiome in idiopathic pulmonary 48:1442-52. 51. Walsh SLF, Wells AU, Desai SR, et al.
fibrosis: what does it mean and what 38. Podolanczuk AJ, Oelsner EC, Barr RG, Multicentre evaluation of multidisciplinary
should we do about it? Am J Respir Crit et al. High-attenuation areas on chest team meeting agreement on diagnosis in
Care Med 2014;190:850-2. computed tomography and clinical respi- diffuse parenchymal lung disease: a case-
25. Misharin AV, Morales-Nebreda L, Reyf ratory outcomes in community-dwelling cohort study. Lancet Respir Med 2016;4:
man PA, et al. Monocyte-derived alveolar adults. Am J Respir Crit Care Med 2017; 557-65.
macrophages drive lung fibrosis and per- 196:1434-42. 52. Rosas IO, Richards TJ, Konishi K, et al.
sist in the lung over the life span. J Exp 39. Putman RK, Hatabu H, Araki T, et al. MMP1 and MMP7 as potential peripheral
Med 2017;214:2387-404. Association between interstitial lung ab- blood biomarkers in idiopathic pulmo-
26. Kitsios GD, Rojas M, Kass DJ, et al. normalities and all-cause mortality. JAMA nary fibrosis. PLoS Med 2008;5(4):e93.
Microbiome in lung explants of idiopathic 2016;315:672-81. 53. White ES, Xia M, Murray S, et al. Plas-
pulmonary fibrosis: a case-control study 40. Hunninghake GM, Hatabu H, Okajima ma surfactant protein-D, matrix metallo-
in patients with end-stage fibrosis. Thorax Y, et al. MUC5B promoter polymorphism proteinase-7, and osteopontin index dis-
2017 August 11 (Epub ahead of print). and interstitial lung abnormalities. N Engl tinguishes idiopathic pulmonary fibrosis
27. Han MK, Zhou Y, Murray S, et al. J Med 2013;368:2192-200. from other idiopathic interstitial pneu-
Lung microbiome and disease progres- 41. Lynch DA, Sverzellati N, Travis WD, monias. Am J Respir Crit Care Med 2016;
sion in idiopathic pulmonary fibrosis: an et al. Diagnostic criteria for idiopathic 194:1242-51.
analysis of the COMET study. Lancet pulmonary fibrosis: a Fleischner Society 54. Yang IV, Luna LG, Cotter J, et al. The
Respir Med 2014;2:548-56. white paper. Lancet Respir Med 2018;6: peripheral blood transcriptome identifies
28. Molyneaux PL, Cox MJ, Willis-Owen 138-53. the presence and extent of disease in idio-
SA, et al. The role of bacteria in the patho- 42. Brownell R, Moua T, Henry TS, et al. pathic pulmonary fibrosis. PLoS One 2012;
genesis and progression of idiopathic The use of pretest probability increases the 7(6):e37708.
pulmonary fibrosis. Am J Respir Crit Care value of high-resolution CT in diagnosing 55. Kim SY, Diggans J, Pankratz D, et al.
Med 2014;190:906-13. usual interstitial pneumonia. Thorax 2017; Classification of usual interstitial pneu-
29. Huang Y, Ma SF, Espindola MS, et al. 72:424-9. monia in patients with interstitial lung
Microbes are associated with host innate 43. Salisbury ML, Xia M, Murray S, et al. disease: assessment of a machine learning
immune response in idiopathic pulmo- Predictors of idiopathic pulmonary fibro- approach using high-dimensional tran-
nary fibrosis. Am J Respir Crit Care Med sis in absence of radiologic honeycomb- scriptional data. Lancet Respir Med 2015;
2017;196:208-19. ing: a cross sectional analysis in ILD pa- 3:473-82.
30. Noth I, Zhang Y, Ma SF, et al. Genetic tients undergoing lung tissue sampling. 56. Pankratz DG, Choi Y, Imtiaz U, et al.
variants associated with idiopathic pul- Respir Med 2016;118:88-95. Usual interstitial pneumonia can be detect-
monary fibrosis susceptibility and mor- 44. Han Q, Luo Q, Xie JX, et al. Diagnos- ed in transbronchial biopsies using ma-
tality: a genome-wide association study. tic yield and postoperative mortality as- chine learning. Ann Am Thorac Soc 2017;
Lancet Respir Med 2013;1:309-17. sociated with surgical lung biopsy for 14:1646-54.
31. Philp CJ, Siebeke I, Clements D, et al. evaluation of interstitial lung diseases: 57. Dowman LM, McDonald CF, Bozinov
ECM crosslinking enhances fibroblast a systematic review and meta-analysis. ski S, et al. Greater endurance capacity
growth and protects against matrix pro- J Thorac Cardiovasc Surg 2015; 149(5): and improved dyspnoea with acute oxy-
teolysis in lung fibrosis. Am J Respir Cell 1394-401.e1. gen supplementation in idiopathic pul-
Mol Biol 2017 October 20 (Epub ahead of 45. Johannson KA, Marcoux VS, Ronksley monary fibrosis patients without resting
print). PE, Ryerson CJ. Diagnostic yield and com- hypoxaemia. Respirology 2017;22:957-64.

58. Dowman LM, McDonald CF, Hill CJ, 73. Raghu G, Selman M. Nintedanib and nary fibrosis (IPF): results from the first
et al. The evidence of benefits of exercise pirfenidone: new antifibrotic treatments in IPF patients study. Am J Respir Crit
training in interstitial lung disease: a ran- indicated for idiopathic pulmonary fibro- Care Med 2017;195:A7560. abstract.
domised controlled trial. Thorax 2017;72: sis offer hopes and raises questions. Am J 88. van den Blink B, Dillingh MR, Ginns
610-9. Respir Crit Care Med 2015;191:252-4. LC, et al. Recombinant human pentraxin-2
59. Valapour M, Lehr CJ, Skeans MA, et al. 74. Vancheri C, Kreuter M, Richeldi L, et al. therapy in patients with idiopathic pul-
OPTN/SRTR 2016 annual data report: lung. Nintedanib with add-on pirfenidone in monary fibrosis: safety, pharmacokinetics
Am J Transplant 2018;18:Suppl 1:363-433. idiopathic pulmonary fibrosis: results of and exploratory efficacy. Eur Respir J 2016;
60. Singer JP, Katz PP, Soong A, et al. Effect the INJOURNEY Trial. Am J Respir Crit 47:889-97.
of lung transplantation on health-related Care Med 2018;197:356-63. 89. Horton MR, Santopietro V, Mathew L,
quality of life in the era of the Lung Allo- 75. The Idiopathic Pulmonary Fibrosis et al. Thalidomide for the treatment of
cation Score: a U.S. prospective cohort Clinical Research Network. Randomized cough in idiopathic pulmonary fibrosis:
study. Am J Transplant 2017;17:1334-45. trial of acetylcysteine in idiopathic pul- a randomized trial. Ann Intern Med 2012;
61. Titman A, Rogers CA, Bonser RS, monary fibrosis. N Engl J Med 2014;370: 157:398-406.
Banner NR, Sharples LD. Disease-specific 2093-101. 90. van Manen MJG, Birring SS, Vancheri
survival benefit of lung transplantation in 76. Oldham JM, Ma SF, Martinez FJ, et al. C, et al. Effect of pirfenidone on cough in
adults: a national cohort study. Am J Trans- TOLLIP, MUC5B, and the response to patients with idiopathic pulmonary fibro-
plant 2009;9:1640-9. N-acetylcysteine among individuals with sis. Eur Respir J 2017;50(4):1701157.
62. Weill D, Benden C, Corris PA, et al. idiopathic pulmonary fibrosis. Am J Respir 91. Abdulqawi R, Dockry R, Holt K, et al.
A consensus document for the selection Crit Care Med 2015;192:1475-82. P2X3 receptor antagonist (AF-219) in re-
of lung transplant candidates: 2014 — an 77. King TE Jr, Albera C, Bradford WZ, fractory chronic cough: a randomised,
update from the Pulmonary Transplanta- et al. Effect of interferon gamma-1b on double-blind, placebo-controlled phase 2
tion Council of the International Society for survival in patients with idiopathic pul- study. Lancet 2015;385:1198-205.
Heart and Lung Transplantation. J Heart monary fibrosis (INSPIRE): a multicentre, 92. Birring SS, Wijsenbeek MS, Agrawal S,
Lung Transplant 2015;34:1-15. randomised, placebo-controlled trial. Lan- et al. A novel formulation of inhaled so-
63. Raghu G, Rochwerg B, Zhang Y, et al. cet 2009;374:222-8. dium cromoglicate (PA101) in idiopathic
An official ATS/ERS/JRS/ALAT clinical 78. Raghu G, Behr J, Brown KK, et al. pulmonary fibrosis and chronic cough:
practice guideline: treatment of idiopathic Treatment of idiopathic pulmonary fibro- a randomised, double-blind, proof-of-con-
pulmonary fibrosis: an update of the 2011 sis with ambrisentan: a parallel, random- cept, phase 2 trial. Lancet Respir Med
clinical practice guideline. Am J Respir ized trial. Ann Intern Med 2013;158:641-9. 2017;5:806-15.
Crit Care Med 2015;192(2):e3-e19. 79. Noth I, Anstrom KJ, Calvert SB, et al. 93. Lindell KO, Liang Z, Hoffman LA, et al.
64. Richeldi L, du Bois RM, Raghu G, et al. A placebo-controlled randomized trial of Palliative care and location of death in de-
Efficacy and safety of nintedanib in idio- warfarin in idiopathic pulmonary fibro- cedents with idiopathic pulmonary fibro-
pathic pulmonary fibrosis. N Engl J Med sis. Am J Respir Crit Care Med 2012;186: sis. Chest 2015;147:423-9.
2014;370:2071-82. 88-95. 94. Collard HR, Ryerson CJ, Corte TJ, et al.
65. King TE Jr, Bradford WZ, Castro-Ber- 80. Marks PW, Witten CM, Califf RM. Acute exacerbation of idiopathic pulmo-
nardini S, et al. A phase 3 trial of pirfeni- Clarifying stem-cell therapy’s benefits and nary fibrosis: an International Working
done in patients with idiopathic pulmonary risks. N Engl J Med 2017;376:1007-9. Group report. Am J Respir Crit Care Med
fibrosis. N Engl J Med 2014;370:2083-92. 81. Lee JS, Collard HR, Anstrom KJ, et al. 2016;194:265-75.
66. Ley B, Swigris J, Day BM, et al. Pirfeni- Anti-acid treatment and disease progres- 95. Dalleywater W, Powell HA, Fogarty
done reduces respiratory-related hospital- sion in idiopathic pulmonary fibrosis: an AW, Hubbard RB, Navaratnam V. Venous
izations in idiopathic pulmonary fibrosis. analysis of data from three randomised thromboembolism in people with idio-
Am J Respir Crit Care Med 2017;196:756-61. controlled trials. Lancet Respir Med 2013; pathic pulmonary fibrosis: a population-
67. Costabel U, Inoue Y, Richeldi L, et al. 1:369-76. based study. Eur Respir J 2014;44:1714-5.
Efficacy of nintedanib in idiopathic pul- 82. Lee JS, Ryu JH, Elicker BM, et al. Gas- 96. Le Jeune I, Gribbin J, West J, Smith C,
monary fibrosis across prespecified sub- troesophageal reflux therapy is associated Cullinan P, Hubbard R. The incidence of
groups in INPULSIS. Am J Respir Crit with longer survival in patients with idio- cancer in patients with idiopathic pulmo-
Care Med 2016;193:178-85. pathic pulmonary fibrosis. Am J Respir nary fibrosis and sarcoidosis in the UK.
68. Nathan SD, Albera C, Bradford WZ, Crit Care Med 2011;184:1390-4. Respir Med 2007;101:2534-40.
et al. Effect of pirfenidone on mortality: 83. Miettinen OS. The need for random- 97. Raghu G, Amatto VC, Behr J, Stowas-
pooled analyses and meta-analyses of clin- ization in the study of intended effects. ser S. Comorbidities in idiopathic pulmo-
ical trials in idiopathic pulmonary fibro- Stat Med 1983;2:267-71. nary fibrosis patients: a systematic litera-
sis. Lancet Respir Med 2017;5:33-41. 84. Kreuter M, Wuyts W, Renzoni E, et al. ture review. Eur Respir J 2015;46:1113-30.
69. Richeldi L, Cottin V, du Bois RM, et al. Antacid therapy and disease outcomes in 98. MacMahon H, Naidich DP, Goo JM,
Nintedanib in patients with idiopathic idiopathic pulmonary fibrosis: a pooled et al. Guidelines for management of inci-
pulmonary fibrosis: combined evidence analysis. Lancet Respir Med 2016;4:381-9. dental pulmonary nodules detected on CT
from the TOMORROW and INPULSIS trials. 85. Gorina E, Richeldi L, Raghu G, et al. images: from the Fleischner Society 2017.
Respir Med 2016;113:74-9. PRAISE, a randomized, placebo-controlled, Radiology 2017;284:228-43.
70. Kolb M, Bonella F, Wollin L. Thera- double-blind phase 2 clinical trial of 99. Moyer VA, U.S. Preventive Services Task
peutic targets in idiopathic pulmonary pamrevlumab (FG-3019) in IPF patients. Force. Screening for lung cancer: U.S. Pre-
fibrosis. Respir Med 2017;131:49-57. Eur Respir J 2017; 50:
Suppl 61:
OA3400. ventive Services Task Force recommenda-
71. Canestaro WJ, Forrester SH, Raghu G, abstract. tion statement. Ann Intern Med 2014;160:
Ho L, Devine BE. Drug treatment of idio- 86. Parker J, Sawtell R, Gagnon L, et al. 330-8.
pathic pulmonary fibrosis: systematic re- PBI-4050 is safe and well tolerated and 100. Wiener RS, Ouellette DR, Diamond
view and network meta-analysis. Chest shows evidence of benefit in idiopathic E, et al. An official American Thoracic
2016;149:756-66. pulmonary fibrosis. Am J Respir Crit Care Society/American College of Chest Physi-
72. Rochwerg B, Neupane B, Zhang Y, et al. Med 2017;195:A7606. abstract. cians policy statement: the Choosing
Treatment of idiopathic pulmonary fibro- 87. Hirani N, MacKinnon A, Nicol L, et al. Wisely top five list in adult pulmonary
sis: a network meta-analysis. BMC Med TD139, a novel inhaled galectin-3 inhibi- medicine. Chest 2014;145:1383-91.
2016;14:18. tor for the treatment of idiopathic pulmo- Copyright © 2018 Massachusetts Medical Society.


Fibrosis Pulmonar Idiopática

Uploaded by

Copyright:

Available Formats

Fibrosis Pulmonar Idiopática

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Fibrosis Pulmonar Idiopática

Uploaded by

Copyright:

Available Formats

The n e w e ng l a n d j o u r na l of m e dic i n e

Dan L. Longo, M.D., Editor

Idiopathic Pulmonary Fibrosis

Cl inic a l Pr e sen tat ion

n engl j med 378;19 nejm.org May 10, 2018 1811

1812 n engl j med 378;19 nejm.org May 10, 2018

The New England Journal of Medicine

Table 1. Clinical Presentation of Idiopathic Pulmonary

n engl j med 378;19 nejm.org May 10, 2018 1813

Environmental Risk Factors

Airway epithelial cells

Increased mucin 5b Latent TGF-β

Type II alveolar Microbiome diversity

Tyrosine Kinase and G-Protein–Coupled Multiple Mechanisms

1814 n engl j med 378;19 nejm.org May 10, 2018

The New England Journal of Medicine

CCP, anti-Ro, anti-La, anti-

ANA; rheumatoid factor; anti-

­antibodies; CK; myoglobin

panel in selected cases

U1RNP, and anti-Jo-1

bution, mosaic ground-

piratory gas trapping,

sive massive fibrosis,

Synovitis, joint deformities, Ground-glass opacities,

Findings Inconsistent with IPF†

ic’s hands, Gottron’s

birds, down or feather bedding,

skin thickening or tightening;

Occupational history and expo-

rash; dry eyes; dry mouth;

VEGF vascular endothelial growth factor, and VEGFR

vascular endothelial growth factor receptor.

ease (Table 2), which are more common in ­phenomenon

matory myopathy (e.g., anti-

ic hypersensitivity pneumonitis. We also look for pneumoconiosis, silicosis,

signs and symptoms of autoimmune conditions,

and we routinely test for antinuclear antibodies;

rheumatoid factor; anti–cyclic citrullinated pep-

U1-RNP, and Jo-1; creatine kinase; and myoglo-

bin. In selected cases, a more extensive panel of

sufficient to rule out IPF. Input from a rheuma-

physical examination, or serologic testing sug-

If no cause can be identified, IPF should be

n engl j med 378;19 nejm.org May 10, 2018 1815

1816 n engl j med 378;19 nejm.org May 10, 2018

The New England Journal of Medicine

n engl j med 378;19 nejm.org May 10, 2018 1817

Table 3. Pharmacologic Management of IPF.*

Variable Nintedanib Pirfenidone

Molecular diagnostic markers, including cir- cannot be overemphasized. Smoking cessation

1818 n engl j med 378;19 nejm.org May 10, 2018

The New England Journal of Medicine

Pulmonary Rehabilitation factor receptors 1, 2, and 3, and platelet-derived

n engl j med 378;19 nejm.org May 10, 2018 1819

1820 n engl j med 378;19 nejm.org May 10, 2018

The New England Journal of Medicine

n engl j med 378;19 nejm.org May 10, 2018 1821

1822 n engl j med 378;19 nejm.org May 10, 2018

antibodies; CK; myoglobin

ease (Table 2), which are more common in phenomenon